Table 3: Hemostatic markers unaffected by warfarin in NVAF patients without a history of an embolic event* and control subjects without a history of thrombotic stroke
Marker	Group; mean value (and SD)†		Difference in means (and 95% CI)	Adjusted p value‡
	NVAF patients without history of event n = 50	Control subjects without history of stroke n = 31
Hemoglobin, g/L	149  (13)	134  (15)	15  (9, 21)	< 0.001
Platelet count, × 109/L	230  (98)	233  (49)	3  ( 35, 29)	0.35
Fibrinogen, g/L	3.7  (0.8)	3.2  (1.1)	0.5  (0.1, 1.0)	0.05
Von Willebrand factor antigen, µ/mL	1.8  (0.6)	1.5  (0.6)	0.3  (0.02, 0.5)	0.26
Factor VIII, µ/mL	1.6  (0.7)	1.3  (0.3)	0.3  (0.02, 0.5)	0.11
Fibrin D­dimer, % of subjects with level < 200, 200-500 and > 500 ng/mL respectively	90, 6, 4	87, 7, 6	--	0.12
Antithrombin III, µ/mL	1.00  (0.15)	1.00  (0.13)	0  ( 0.06, 0.06)	0.78
*Embolic event = transient ischemic attack or embolic stroke. †Unless otherwise stated. ‡Determined by analysis of variance (ANOVA), for difference between groups after adjustment for age and sex.

[Return to text]